These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32655688)

  • 1. Eculizumab as a promising treatment in thymoma-associated myasthenia gravis.
    Vélez-Santamaría V; Nedkova V; Díez L; Homedes C; Alberti MA; Casasnovas C
    Ther Adv Neurol Disord; 2020; 13():1756286420932035. PubMed ID: 32655688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.
    Oyama M; Okada K; Masuda M; Shimizu Y; Yokoyama K; Uzawa A; Kawaguchi N; Ikeguchi R; Hoshino Y; Hatano T; Ozawa Y; Nakahara J; Aizawa H; Kitagawa K; Hattori N; Kuwabara S; Murai H; Suzuki S
    Ther Adv Neurol Disord; 2020; 13():1756286420904207. PubMed ID: 32215054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
    Jiao L; Li H; Guo S
    J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.
    Murai H; Suzuki S; Hasebe M; Fukamizu Y; Rodrigues E; Utsugisawa K
    Ther Adv Neurol Disord; 2021; 14():17562864211001995. PubMed ID: 33796147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
    Uzawa A; Kuwabara S
    Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
    Datta S; Singh S; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
    Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
    Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistent improvement with eculizumab across muscle groups in myasthenia gravis.
    Mantegazza R; O'Brien FL; Yountz M; Howard JF;
    Ann Clin Transl Neurol; 2020 Aug; 7(8):1327-1339. PubMed ID: 32700461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series.
    Levine TD
    Am J Case Rep; 2019 Jul; 20():965-970. PubMed ID: 31278249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review.
    Waheed W; Newman E; Aboukhatwa M; Moin M; Tandan R
    Ther Clin Risk Manag; 2022; 18():699-719. PubMed ID: 35855752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myasthenia gravis with achalasia secondary to thymoma: a case report and literature review.
    Haridy NA; Khedr EM; Hasan AM; Maghraby AA; Abdelmohsen E; Aly AM
    Egypt J Neurol Psychiatr Neurosurg; 2023; 59(1):34. PubMed ID: 36936607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab.
    Mimori M; Komatsu T; Maku T; Mitsumura H; Iguchi Y
    Neurol Sci; 2022 Jul; 43(7):4081-4083. PubMed ID: 35364770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seronegative myasthenia gravis associated with malignant thymoma.
    Richards J; Howard JF
    Neuromuscul Disord; 2017 May; 27(5):417-418. PubMed ID: 28238572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report.
    Vu T; Harvey B; Suresh N; Farias J; Gooch C
    Case Rep Neurol; 2021; 13(1):65-72. PubMed ID: 33708096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
    Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myasthenia gravis].
    Müllges W; Stoll G
    Nervenarzt; 2019 Oct; 90(10):1055-1066. PubMed ID: 31538208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
    Uzawa A; Ozawa Y; Yasuda M; Kuwabara S
    J Neuroimmunol; 2020 Dec; 349():577424. PubMed ID: 33068973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.